Allogeneic hematopoietic stem cell transplantation from HLA6/8-4/8 matched related donor for poor prognostic or refractory hematologic malignancy and solid tumor - Ibaraki Children's Hospital phase II study
- Conditions
- Acute leukemia, malignant lymphoma, and solid tumor
- Registration Number
- JPRN-UMIN000027010
- Lead Sponsor
- Ibaraki Children's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Not provided
(1)Germ line chromosomal abnormality other than trisomy 21 (2)Concurrent or prior malignant disease other than the original disease in interest or prior organ transplantation other than hematopoietic cell transplantation (3)Congenital or acquired immunodeficiency (4)Uncontrolled fungal, bacterial, or viral infection (including tuberculosis of HIV) (5)Pregnant, lactating, or highly suspected to be pregnant (6)Corrected QT interval by Fridericia, more than 0.45 second (7)Active hemorrhage in central nervous system, fulfilling grade more than 3 on CTCAE version 4.0 (8)Consciousness disturbance, score less than 14 on Glasgow Coma Scale (9)Obesity, by more than 30% of average weight for age. (10)Considered to be unsuitable for entry for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease free survival rate at day 60 after transplantation
- Secondary Outcome Measures
Name Time Method